Market Access BIO Boston: 2025 is shaping up to be a year of challenge – b... What were the major themes to come out of BIO Boston 2025? Despite global events in the background, a fair amount of positivity.
News Amid sector disruption, biotech must focus on 'fundamentals'... The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
News Welsh biotech Draig emerges with $140m in financing Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.
Oncology AACR 2025: New modalities and remaining challenges Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges
News GRIN raises $140m for epilepsy drug, and other financings Our round-up of recent biotech financings includes rounds for GRIN Therapeutics, GlycoEra, Syndeio, Juvenescence, and Vima Therapeutics.
News Pathos AI's big $365m Series D, and other bio financings Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.
News Agios mulls early FDA filing for sickle cell therapy Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.